Internal Medicine Alert – August 15, 2013
August 15, 2013
View Issues
-
Role of Fish Oil in Secondary Cardiovascular
In patients with multiple cardiovascular risk factors, daily treatment with n-3 fatty acids did not reduce cardiovascular mortality and morbidity. -
Physician Communication and Prostate Cancer Screening
A brief web intervention improved shared decision making regarding prostate cancer screening. -
Digoxin and Mortality in Atrial Fibrillation
Digoxin has no association with mortality in patients with heart failure in the AFFIRM study when bias is removed with a careful propensity-matched analysis. -
Brief Report by Matthew Fink, MD
The authors compared potential risk factors, clini-cal symptoms, diagnostic delay, and 3-month outcome between spontaneous internal carotid artery dissection (sICAD) and spontaneous vertebral artery dissection (sVAD). -
Pharmacology Update
The fda has approved a higher dose of the rivastigmine transdermal system (13.3 mg/24 hours) for the treatment of Alzheimer's disease (AD). Lower-dose patches were previously approved for mild-to-moderate disease. Rivastigamine is a reversible acetylcholinesterase inhibitor. The transdermal system is marketed by Novartis as Exelon. -
Clinical Briefs By Louis Kuritzky
Once-daily Tadalafil for ED: Efficacy and Safety; Psychological Disorders: How to Give Patients What They Want and What They Need; Reducing Stroke Risk After TIA or Minor Ischemic Stroke -
ECG Review: Which Vessel is Occluded?
The impression is acute infero-posterior infarction, with possible lateral and right ventricular involvement. In most patients, the right coronary artery (RCA) supplies the right ventricle and posterior and inferior walls of the left ventricle.